Menu
Annual · values20252024202320222021
Operating Cash Flow7.86 M USD3.45 M USD-552958 USD-756716 USD
Depreciation & Amortization495698 USD525295 USD607138 USD
Stock-Based Compensation3.96 M USD20.87 M USD
Capital Expenditures479034 USD576674 USD291856 USD
Cash Flow from Investing-478438 USD-565034 USD130.58 M USD-3.00 M USD
Cash Flow from Financing4.03 M USD2.02 M USD-130.26 M USD3.00 M USD
Dividends Paid
Stock Buybacks133.12 M USD
Free Cash Flow7.38 M USD2.87 M USD-844814 USD

Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on the development and commercialization of innovative drug delivery systems. It aims to improve patient adherence and experience by providing new methods for drug delivery, such as oral thin films and transdermal systems. Cure Pharmaceutical's technologies are designed to enhance the bioavailability, efficacy, and safety of existing pharmaceutical compounds while also providing a platform for new drug formulations. This plays a vital role in several therapeutic areas, including pain management, oncology, and central nervous system disorders. By leveraging cutting-edge technology and partnerships within the pharmaceutical industry, Cure Pharmaceutical Holding Corp. contributes to the advancement of personalized and precision medicine, addressing unmet medical needs and broadening the spectrum of delivery options in healthcare markets.